AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Am J Translational Res 2011;3(2):133-138

Review Article
Targeting transcription factor Stat5a/b as a therapeutic strategy for
prostate cancer

Zhiyong Liao, Marja T. Nevalainen

Department of Cancer Biology, Department of Medical Oncology, and Department of Urology, Kimmel Cancer
Center, Thomas Jefferson University, Philadelphia, PA, USA

Received November 15, 2010; Accepted November 20, 2010; Epub November 21, 2010; Published January 1,
2011

Abstract: Signal transducer and activator of transcription 5 (Stat5) is critical for the viability and growth of human
prostate cancer cells in culture and for prostate xenograft tumors in nude mice. The expression of nuclear active
Stat5a/b is associated with high histological grades of clinical prostate cancers, and the presence of active
Stat5a/b in prostate cancer predicts early disease recurrence. Stat5a/b and androgen receptor signaling
pathways functionally synergize in prostate cancer cells, and recent work suggests that Stat5a/b may be involved
in the progression of prostate cancer to metastatic disease. Here, we review the biological functions of Stat5a/b in
prostate cancer and potential strategies to target the prolactin receptor (PrlR)/Jak2/Stat5 signaling pathway for
therapy development for prostate cancer. (AJTR1011004).

Keywords: Prostate cancer, therapy development, prolactin receptor-Jak2-Stat5a/b signaling pathway

Full Text  PDF

Address all correspondence to:
Marja T. Nevalainen, MD, PhD
Dept. of Cancer Biology, Urology, Medical Oncology
Kimmel Cancer Center,
Thomas Jefferson University,
233 S. 10th Street, BLSB 309
Philadelphia, PA 19107.
Email:
marja.nevalainen@jefferson.edu or
Marja.Nevalainen@kimmelcancercenter.org
Tel: 215-503-9250
Fax: 215-503-9245